Physician profile
John M Raines
NPI 1679587737
$1,118.95
in general payments reported to CMS, 2019-2025
13 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2021: $17.27 · 2022: $184 · 2023: $287 · 2024: $281 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $199.80 | 2022-2024 | Mounjaro |
| Abbvie INC. | $143.35 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $130.39 | 2021-2025 | Airsupra, Farxiga |
| Shield Therapeutics INC | $129.98 | 2023-2025 | Accrufer |
| Amgen INC. | $116.64 | 2019-2025 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $108.32 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $93.78 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $63.07 | 2025 | |
| Boston Scientific Corporation | $37.70 | 2024-2025 | General - Pain Management |
| Pfizer INC. | $36.95 | 2025 | |
| Glaxosmithkline, LLC. | $21.43 | 2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $19.74 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $17.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Raines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.